Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 8/20 | 0.43 |
| ▸ | INSR | P06213 | 5/20 | 0.39 |
| ▸ | MET | P08581 | 5/20 | 0.39 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.36 |
| ▸ | MERTK | Q12866 | 2/20 | 0.36 |
| ▸ | MAP3K7 | O43318 | 3/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3493833 | 0.93 | SYK (0.43) | SYKINSRMETCDK19ALK | |
| SCHEMBL3497189 | 0.91 | SYK (0.39) | SYKINSRMETCDK19ALK | |
| SCHEMBL3496133 | 0.88 | CYP1A2 (0.42) | SYKINSRMETTYRO3MERTK | |
| SCHEMBL3495365 | 0.84 | SYK (0.39) | SYKINSRMETCDK19ALK | |
| SCHEMBL3496746 | 0.84 | SYK (0.38) | SYKINSRMETCDK19ALK | |
| SCHEMBL3494871 | 0.82 | SYK (0.45) | SYK | |
| SCHEMBL3495369 | 0.81 | CYP1A2 (0.42) | SYKINSRMETMAP3K7IRAK4 | |
| SCHEMBL3495849 | 0.80 | INSR (0.36) | SYKINSRMET | |
| SCHEMBL3495846 | 0.78 | INSR (0.36) | SYKINSRMETALKTYRO3 | |
| SCHEMBL3497069 | 0.77 | SYK (0.38) | SYKINSRMETCDK19ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | claimed |
| EP-2183225-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | claimed |
| WO-2009012421-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | WO | claimed |
| US-8993585-B2 | Cyclic amine substituted pyrimidinediamines as PKC inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| EP-2183225-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009012421-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | PRKCH, PKD2, PRKCQ | SYK 460/4885INSR 1712/4885MET 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.